MeSH D007943 - hairy cell leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Cladribine | Cladribine |  | 2011-10-06 |  |  |
| Johnson & Johnson | Cladribine | Leustatin |  | 1993-02-26 |  |  |
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus |  | 2004-06-04 |  |  |
| Interferon alfa-2a | Roferon-A |  | 1986-06-04 |  |  | |
| AstraZeneca | Moxetumomab pasudotox | Lumoxiti |  | 2021-02-08 |  |  |
| Merck & Co | Cladribine | Mavenclad |  | 2017-08-22 |  |  |
| Rising Pharmaceuticals | Pentostatin | Pentostatin |  | 2014-09-19 |  |  |
| Hospira | Pentostatin | Nipent |  | 1991-10-11 |  |  |
| Hikma Pharmaceuticals | Cladribine | Cladribine |  | 2000-02-28 |  |  |
| West-Ward Pharmaceutical | Pentostatin | Pentostatin |  | 2007-08-07 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
61%35/57
Phase 2
2%1/50
Phase 3
100%15/15
Approved: 12Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use